Patents Assigned to Emergent Product Development Seattle, LLC
-
Publication number: 20120213773Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: February 14, 2012Publication date: August 23, 2012Applicant: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Peter A. Thompson
-
Patent number: 8197810Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: GrantFiled: October 8, 2010Date of Patent: June 12, 2012Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
-
Patent number: 8188237Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: GrantFiled: October 8, 2010Date of Patent: May 29, 2012Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
-
Publication number: 20120100139Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.Type: ApplicationFiled: October 2, 2009Publication date: April 26, 2012Applicant: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Peter Robert Baum, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
-
Patent number: 8147835Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: GrantFiled: August 13, 2009Date of Patent: April 3, 2012Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
-
Publication number: 20120034245Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.Type: ApplicationFiled: June 12, 2007Publication date: February 9, 2012Applicant: Emergent Product Development Seattle, LLCInventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
-
Patent number: 8106161Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: GrantFiled: March 23, 2005Date of Patent: January 31, 2012Assignee: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
-
Publication number: 20110223164Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type lgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.Type: ApplicationFiled: March 2, 2011Publication date: September 15, 2011Applicant: Emergent Product Development Seattle, LLCInventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
-
Publication number: 20110217302Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.Type: ApplicationFiled: October 9, 2009Publication date: September 8, 2011Applicant: Emergent Product Development Seattle, LLCInventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan